81 related articles for article (PubMed ID: 19419794)
1. Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors.
Pérez-Rial S; García-Gutiérrez MS; Molina JA; Pérez-Nievas BG; Ledent C; Leiva C; Leza JC; Manzanares J
Neurobiol Aging; 2011 Apr; 32(4):631-45. PubMed ID: 19419794
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of CB2 cannabinoid receptors results in neuroprotection against behavioral and neurochemical alterations induced by intracaudate administration of 6-hydroxydopamine.
Ternianov A; Pérez-Ortiz JM; Solesio ME; García-Gutiérrez MS; Ortega-Álvaro A; Navarrete F; Leiva C; Galindo MF; Manzanares J
Neurobiol Aging; 2012 Feb; 33(2):421.e1-16. PubMed ID: 20980074
[TBL] [Abstract][Full Text] [Related]
3. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
Darmopil S; Martín AB; De Diego IR; Ares S; Moratalla R
Biol Psychiatry; 2009 Sep; 66(6):603-13. PubMed ID: 19520364
[TBL] [Abstract][Full Text] [Related]
4. Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of l-DOPA-induced dyskinesia.
Johansson PA; Andersson M; Andersson KE; Cenci MA
Neurobiol Dis; 2001 Apr; 8(2):220-39. PubMed ID: 11300719
[TBL] [Abstract][Full Text] [Related]
5. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
Pavón N; Martín AB; Mendialdua A; Moratalla R
Biol Psychiatry; 2006 Jan; 59(1):64-74. PubMed ID: 16139809
[TBL] [Abstract][Full Text] [Related]
6. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
Synapse; 2006 Sep; 60(3):239-50. PubMed ID: 16739115
[TBL] [Abstract][Full Text] [Related]
7. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
Kobylecki C; Cenci MA; Crossman AR; Ravenscroft P
J Neurochem; 2010 Jul; 114(2):499-511. PubMed ID: 20456008
[TBL] [Abstract][Full Text] [Related]
8. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA.
Cenci MA; Lee CS; Björklund A
Eur J Neurosci; 1998 Aug; 10(8):2694-706. PubMed ID: 9767399
[TBL] [Abstract][Full Text] [Related]
9. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
[TBL] [Abstract][Full Text] [Related]
10. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
Pérez V; Sosti V; Rubio A; Barbanoj M; Rodríguez-Alvarez J; Kulisevsky J
Eur J Pharmacol; 2007 Dec; 576(1-3):83-90. PubMed ID: 17888901
[TBL] [Abstract][Full Text] [Related]
11. The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy.
Eskow KL; Gupta V; Alam S; Park JY; Bishop C
Pharmacol Biochem Behav; 2007; 87(3):306-14. PubMed ID: 17553556
[TBL] [Abstract][Full Text] [Related]
12. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
[TBL] [Abstract][Full Text] [Related]
13. Impaired behavioural and molecular adaptations to dopamine denervation and repeated L-DOPA treatment in Nur77-knockout mice.
St-Hilaire M; Bourhis E; Lévesque D; Rouillard C
Eur J Neurosci; 2006 Aug; 24(3):795-805. PubMed ID: 16930409
[TBL] [Abstract][Full Text] [Related]
14. A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function.
Lundblad M; Picconi B; Lindgren H; Cenci MA
Neurobiol Dis; 2004 Jun; 16(1):110-23. PubMed ID: 15207268
[TBL] [Abstract][Full Text] [Related]
15. Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats.
Marin C; Jiménez A; Tolosa E; Bonastre M; Bové J
Synapse; 2004 Feb; 51(2):140-50. PubMed ID: 14618681
[TBL] [Abstract][Full Text] [Related]
16. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
Morissette M; Goulet M; Calon F; Falardeau P; Blanchet PJ; Bédard PJ; Di Paolo T
Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337
[TBL] [Abstract][Full Text] [Related]
17. MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons.
Van De Witte SV; Groenewegen HJ; Voorn P
Synapse; 2002 Jan; 43(1):1-11. PubMed ID: 11746728
[TBL] [Abstract][Full Text] [Related]
18. Spontaneous cannabinoid withdrawal produces a differential time-related responsiveness in cannabinoid CB1 receptor gene expression in the mouse brain.
Oliva JM; Ortiz S; Palomo T; Manzanares J
J Psychopharmacol; 2004 Mar; 18(1):59-65. PubMed ID: 15107186
[TBL] [Abstract][Full Text] [Related]
19. A 6-hydroxydopamine-induced selective parkinsonian rat model: further biochemical and behavioral characterization.
Thomas J; Wang J; Takubo H; Sheng J; de Jesus S; Bankiewicz KS
Exp Neurol; 1994 Apr; 126(2):159-67. PubMed ID: 7925817
[TBL] [Abstract][Full Text] [Related]
20. Repeated administration of the monoamine reuptake inhibitor BTS 74 398 induces ipsilateral circling in the 6-hydroxydopamine lesioned rat without sensitizing motor behaviours.
Lane EL; Cheetham SC; Jenner P
Eur J Neurosci; 2005 Jan; 21(1):179-86. PubMed ID: 15654855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
